Format

Send to

Choose Destination
Genes Dev. 2016 Dec 15;30(24):2669-2683. doi: 10.1101/gad.291021.116.

PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance.

Author information

1
Diabetes Center, Department of Medicine, University of California at San Francisco, San Francisco, California 94143, USA.
2
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan 48109, USA.
3
Wolfson Wohl Cancer Research Center, University of Glasgow, Glasgow G61 1BD, Scotland.
4
Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York 11794, USA.
5
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA.
6
Department of Medicine/ Hematology and Oncology, University of California at San Francisco, San Francisco, California 94143, USA.
7
Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37240, USA.
8
Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA.

Abstract

Aberrant activation of embryonic signaling pathways is frequent in pancreatic ductal adenocarcinoma (PDA), making developmental regulators therapeutically attractive. Here we demonstrate diverse functions for pancreatic and duodenal homeobox 1 (PDX1), a transcription factor indispensable for pancreas development, in the progression from normal exocrine cells to metastatic PDA. We identify a critical role for PDX1 in maintaining acinar cell identity, thus resisting the formation of pancreatic intraepithelial neoplasia (PanIN)-derived PDA. Upon neoplastic transformation, the role of PDX1 changes from tumor-suppressive to oncogenic. Interestingly, subsets of malignant cells lose PDX1 expression while undergoing epithelial-to-mesenchymal transition (EMT), and PDX1 loss is associated with poor outcome. This stage-specific functionality arises from profound shifts in PDX1 chromatin occupancy from acinar cells to PDA. In summary, we report distinct roles of PDX1 at different stages of PDA, suggesting that therapeutic approaches against this potential target need to account for its changing functions at different stages of carcinogenesis. These findings provide insight into the complexity of PDA pathogenesis and advocate a rigorous investigation of therapeutically tractable targets at distinct phases of PDA development and progression.

KEYWORDS:

EMT; dedifferentiation; pancreatic cancer; pancreatitis

PMID:
28087712
PMCID:
PMC5238727
DOI:
10.1101/gad.291021.116
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center